A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors

Naing A.Gainor J.F.Gelderblom H.Forde P.M.Butler M.O.CHIA-CHI LINSharma S.Ochoa De Olza M.Varga A.Taylor M.Schellens J.H.M.Wu H.Sun H.Silva A.P.Faris J.Mataraza J.Cameron S.Bauer T.M.2022-09-152022-09-1520202051-1426https://www.scopus.com/inward/record.uri?eid=2-s2.0-85082024869&doi=10.1136%2fjitc-2020-000530&partnerID=40&md5=e02301dbaec0e5ebb48477c724379f53https://scholars.lib.ntu.edu.tw/handle/123456789/620239[SDGs]SDG3A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumorsjournal article10.1136/jitc-2020-000530321796332-s2.0-85082024869